2. Search Result
Search Result
Results for "

CHO-K1

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

11

Peptides

1

MCE Kits

3

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99870
    Eblasakimab

    ASLAN004; CSL-334; MK-6105

    		 Interleukin Related Others
    Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells [1].
    Eblasakimab
  • HY-108003
    MM 07

    		Apelin Receptor (APJ) Cardiovascular Disease
    MM 07 is a biased apelin receptor agonist, with a KD of 300 nM in CHO-K1 cells and a KD of 172 nM in human heart.
    MM 07
  • HY-136895
    AZ12672857

    		Prostaglandin Receptor Cancer
    AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM) [1].
    AZ12672857
  • HY-P990009
    Nisevokitug

    NIS-793

    		 TGF-beta/Smad Cancer
    Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells [1].
    Nisevokitug
  • HY-P5872
    Jingzhaotoxin XI

    JZTX-XI

    		 Sodium Channel Neurological Disease
    Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC50 of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC50=1.18±0.2 μM) of Nav1.5 expressed in Chinese hamster ovary (CHO-K1) cells [1].
    Jingzhaotoxin XI
  • HY-124104
    Aldicarb sulfoxide

    		Drug Metabolite Cardiovascular Disease Metabolic Disease
    Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish [1] .
    Aldicarb sulfoxide
  • HY-124104S
    Aldicarb sulfoxide-d3

    		Isotope-Labeled Compounds Metabolic Disease
    Aldicarb sulfoxide-d3 is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish [1] .
    Aldicarb sulfoxide-d3
  • HY-117617
    CAY10669

    		Histone Acetyltransferase Cancer
    CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC50 of 662 μM [1]. CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells [1] .
    CAY10669
  • HY-100962A
    AG 99

    Tyrphostin 46; Tyrphostin AG 99

    		 Tyrosinase Cancer
    AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases [1].
    AG 99
  • HY-P99888
    Pimurutamab

    		EGFR Others
    Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells [1].
    Pimurutamab
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake [1].
    Survodutide
  • HY-P0165B
    Taspoglutide acetate

    ITM077 acetate; R1583 acetate; BIM51077 acetate

    		 GLP Receptor Metabolic Disease
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model [1] .
    Taspoglutide acetate
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake [1].
    Survodutide TFA
  • HY-123335
    L-796,778

    		Somatostatin Receptor Others
    L-796,778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796,778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM [1].
    L-796,778
  • HY-161247
    5-HT2A antagonist 2

    		5-HT Receptor Metabolic Disease
    5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 [1].
    5-HT2A antagonist 2
  • HY-132225
    SB 206553

    		5-HT Receptor Inflammation/Immunology
    SB 206553 is a 5-HT2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT2A), 7.7 nM (5-HT2B) and 7.8 nM (5-HT2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders [1].
    SB 206553
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-P3789
    Prolactin-Releasing Peptide (12-31), rat

    		Orphan Receptor Metabolic Disease
    Prolactin-Releasing Peptide (12-31), rat is a fragment of the prolactin releasing peptide (PrRP). Prolactin-Releasing Peptide (12-31), rat shows high affinity for GPR10 receptors. Prolactin-Releasing Peptide (12-31), stimulates calcium mobilization in CHOK1 cells transfected with the PrRP receptor [1] .
    Prolactin-Releasing Peptide (12-31), rat
  • HY-131664
    EP3 antagonist 2

    		Prostaglandin Receptor Others
    EP3 antagonist 2 (Compound Exp 1) is a potent and selective EP3 receptor antagonist. EP3 antagonist 2 has a strong binding affinity for the human EP3 receptor (Ki: 3.3 nM) and significant antagonistic activity (IC50: 30.8 nM, determined by cellular cAMP levels) [1].
    EP3 antagonist 2
  • HY-103120
    Org37684

    		5-HT Receptor Neurological Disease
    Org37684 is a highly potent 5-HT2C receptor agonist (pEC50=8.17). Org37684 exhibits a rank order of potency of 5-HT2C>5-HT2B>5-HT2A. Its selectivity for the 5-HT2C receptor is approximately 2.5 times over the 5-HT2B (pEC50=7.96) and ten times for the 5-HT2A (pEC50=7.11) receptor [1].
    Org37684
  • HY-134661
    (S)-CVN424

    		GPR6 Neurological Disease
    (S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease [1].
    (S)-CVN424
  • HY-P10378
    GPR10 agonist 1

    		GnRH Receptor Metabolic Disease
    GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC50 values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity [1].
    GPR10 agonist 1
  • HY-P3840
    Head activator neuropeptide

    		Orphan Receptor Neurological Disease Cancer
    Head activator neuropeptide is a mitogen for mammalian cell lines of neuronal or neuroendocrine origin. Head activator neuropeptide signals by binding GPR37 and stimulates cells to enter mitosis [1].
    Head activator neuropeptide
  • HY-123596
    LAS191859

    		Prostaglandin Receptor Inflammation/Immunology
    LAS191859 is an orally active, potent and selective CRTh2 antagonist with an IC50 of 9.58 nM against human CRTh2. LAS191859 can be used for the research of chronic asthma [1].
    LAS191859
  • HY-112469
    ERK Inhibitor II (Negative control)

    		ERK Insulin Receptor Metabolic Disease
    ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes [1] .
    ERK Inhibitor II (Negative control)
  • HY-16765A
    Axelopran sulfate

    TD-1211 sulfate

    		 Opioid Receptor Neurological Disease
    Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
    Axelopran sulfate
  • HY-128207
    SID7970631

    		Orphan Receptor Cancer
    SID7970631, as an isoquinolinone analog, is a potent and selective submicromolar SF-1 inhibitor (IC50=255 nM). SID7970631 can be used for the research of cancer [1] .
    SID7970631
  • HY-162356
    PD-L1-IN-4

    		PD-1/PD-L1 Cancer
    PD-L1-IN-4 (Compound X18) is an orally active PD-L1 inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC50 = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC50 = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer [1].
    PD-L1-IN-4
  • HY-19443
    UCB-35440

    		Histamine Receptor Lipoxygenase Inflammation/Immunology
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation [1] .
    UCB-35440
  • HY-16765
    Axelopran

    TD-1211

    		 Opioid Receptor Neurological Disease
    Axelopran (TD-1211) is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
    Axelopran
  • HY-149014
    OX2R-IN-1

    		Orexin Receptor (OX Receptor) Neurological Disease
    OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life [1].
    OX2R-IN-1
  • HY-155553
    GPR119 agonist 2

    		GPR119 Metabolic Disease
    GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes [1].
    GPR119 agonist 2
  • HY-14840A
    (R)-Phenylpiracetam

    MRZ 9547

    		 Dopamine Transporter Neurological Disease Inflammation/Immunology
    (R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (Ki: 14.8 μM; IC50: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders [1] .
    (R)-Phenylpiracetam
  • HY-P1185
    Antagonist G

    		Vasopressin Receptor Apoptosis Cardiovascular Disease Cancer
    Antagonist G is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy [1] .
    Antagonist G
  • HY-P2385
    Fmoc-Val-Ser(psi(Me,Me)pro)-OH

    		Amino Acid Derivatives Others
    Fmoc-Val-Ser(psi(Me,Me)pro)-OH is a dipeptide.
    Fmoc-Val-Ser(psi(Me,Me)pro)-OH
  • HY-P1185A
    Antagonist G TFA

    		Vasopressin Receptor Apoptosis Cancer
    Antagonist G TFA is a potent vasopressin antagonist. Antagonist G is also a weak antagonist of GRP and Bradykinin. Antagonist G induces AP-1 transcription and sensitizes cells to chemotherapy [1] .
    Antagonist G TFA
  • HY-149247
    Antipsychotic agent-2

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Antipsychotic agent-2 (Compound 11) is a potent antipsychotic agent. Antipsychotic agent-2 shows affinities for 5-HT1A, 5-HT2A, 5-HT2C, D2 and H1 receptors with Kis of 56.6, 66.7, 552, 596 and 1140 nM, respectively. Antipsychotic agent-2 has BBB permeability [1].
    Antipsychotic agent-2
  • HY-19778
    (R)-BPO-27
    3 Publications Verification

    		 CFTR Autophagy Inflammation/Immunology
    (R)-BPO-27, the R enantiomer of BPO-27, is a potent, orally active and ATP-competitive CFTR inhibitor with an IC50 of 4 nM.
    (R)-BPO-27
  • HY-151884
    FUBP1-IN-2

    		c-Myc Cancer
    FUBP1-IN-2 (compound 9) is a potent FUBP1 (far upstream binding protein 1) inhibitor. FUBP1-IN-2 inhibits the KH4 FUBP1-FUSE interaction in a gel shift assay. FUBP1-IN-2 binds to FUBP1 in a ChIP assay. FUBP1-IN-2 reduces both c-Myc mRNA and protein expression, increases p21 mRNA and protein expression, and depletes intracellular polyamines [1].
    FUBP1-IN-2
  • HY-A0148
    Halofantrine

    SKF-102886 free base; WR-171669

    		 Parasite Potassium Channel Infection Cancer
    Halofantrine (SKF-102886 free base) is a highly lipophilic antimalarial active against Chloroquine-resistant strains of Plasmodium falciparum [1]. Halofantrine blocks HERG potassium channels .
    Halofantrine
  • HY-W020790
    Sialyl-Lewis X

    sLeX

    		 Endogenous Metabolite Inflammation/Immunology
    Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) [1]. Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability?to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .
    Sialyl-Lewis X
  • HY-14939A
    Vapitadine hydrochloride

    		Histamine Receptor Inflammation/Immunology
    Vapitadine hydrochloride (Compound 3a) is a selective, orally active and nonsedating antihistamine agent, which exhibits a good binding affinity with human cloned histamine H1 receptor with a Ki of 19 nM. Vapitadine hydrochloride decreases the histamine-induced lethality (ED50 is 0.056-1.2 mg/kg), antagonizes the cutaneous reactions to histamine (ED50 is 0.51-1.4 mg/kg) in rats [1].
    Vapitadine hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: